Frankfurt
03.10.25 | 15:29
5,250 Euro
+3,96 % +0,200
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Inventiva Names Andrew Obenshain CEO | 4 | RTTNews | ||
| Mi | INVENTIVA: Inventiva Appoints Andrew Obenshain as Chief Executive Officer | 247 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), October 1, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| Mo | Inventiva S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mo | INVENTIVA: Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update | 539 | GlobeNewswire (Europe) | Cash and cash equivalents at €146.7 million including €24.6 million in short-term deposits1 as of June 30, 2025Receipt of the gross proceeds of €115.6 million from the second tranche of the structured... ► Artikel lesen | |
| Mo | Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings | 3 | Benzinga.com | ||
| 26.09. | Preview: Inventiva's Earnings | 1 | Benzinga.com | ||
| 24.09. | INVENTIVA: Inventiva to Host Analyst and Investor Event on October 8, 2025 | 286 | GlobeNewswire (Europe) | Program will include an update on the Company's lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026Three renowned international experts and a patient... ► Artikel lesen | |
| 04.09. | INVENTIVA: Inventiva to Participate in Upcoming September Investor Conferences | 380 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), September 4, 2025 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused... ► Artikel lesen | |
| 02.09. | Inventiva stock price target raised to $13 from $9 at Guggenheim | 2 | Investing.com | ||
| 02.09. | Guggenheim hebt Kursziel für Inventiva auf 13 US-Dollar an | 5 | Investing.com Deutsch | ||
| 27.08. | Inventiva surges as Piper Sandler issues bullish view citing lead asset | 5 | Seeking Alpha | ||
| 27.08. | Piper Sandler initiates Inventiva stock with Overweight rating on MASH potential | 3 | Investing.com | ||
| 27.08. | Piper Sandler startet Coverage für Inventiva mit "Overweight" - MASH-Potenzial im Fokus | 4 | Investing.com Deutsch | ||
| 11.08. | INVENTIVA: Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference | 611 | GlobeNewswire (Europe) | Daix) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH")... ► Artikel lesen | |
| 31.07. | INVENTIVA: Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux | 456 | GlobeNewswire (Europe) | Daix (France), New York (New York, United States), July 31, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the... ► Artikel lesen | |
| 29.07. | INVENTIVA: Inventiva Reports Preliminary 2025 First-Half Financial Information | 1.105 | GlobeNewswire (Europe) | Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025Revenues of €4.5 million recorded in H1 2025
Daix (France), New York City (New York, United... ► Artikel lesen | |
| 09.07. | Inventiva beruft neue Führungskräfte für Forschung & Entwicklung und regulatorische Angelegenheiten | 8 | Investing.com Deutsch | ||
| 09.07. | Inventiva appoints new R&D president and regulatory affairs executive | 2 | Investing.com | ||
| 09.07. | INVENTIVA: Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance | 437 | GlobeNewswire (Europe) | Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MDMartine Zimmermann, PharmD, joins as Executive Vice President... ► Artikel lesen | |
| 09.07. | Inventiva Receives $10 Mln Milestone Payment From CTTQ For MASH Drug Development | 2 | RTTNews |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 4,880 | +1,46 % | Aurora Cannabis Is Spiking. Barchart Options Data Tells Us ACB Stock Could Be Headed Here Next. | ||
| CANOPY GROWTH | 1,178 | +1,73 % | As Trump Promotes CBD, Should You Buy, Sell, or Hold Canopy Growth Stock? | ||
| TILRAY BRANDS | 1,375 | -0,15 % | High Times an der Börse: Trump entfacht Cannabis-Fieber - Tilray plus 60 Prozent, Sektor eskaliert! | © Foto: UnsplashTrump hat mit einem CBD-Video pure Kaufpanik entfacht: Cannabis-Aktien sind daraufhin am Montag zweistellig haussiert, die Tilray-Aktie ist um sagenhafte 60 Prozent explodiert.Cannabis-Aktien... ► Artikel lesen | |
| TEVA | 17,350 | +0,87 % | Teva Pharmaceutical: Teva's Journey to 100% Renewable Electricity: Bold Targets, Bold Solutions | NORTHAMPTON, MA / ACCESS Newswire / September 29, 2025 / Reaching 100% renewable electricity in 10 years - that's a bold target. And bold targets require bold solutions.One way Teva is working toward... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 345,55 | -0,16 % | Vertex Pharmaceuticals - Schlechte Nachrichten zur Pipeline bereiten Investoren Schmerzen | ||
| ARZNEIWERK AG VIDA | 0,460 | +43,75 % | EQS-HV: Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 04.09.2025 in Berlin mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG | EQS-News: Arzneiwerk AG VIDA
/ Bekanntmachung der Einberufung zur Hauptversammlung
Arzneiwerk AG VIDA: Bekanntmachung der Einberufung zur Hauptversammlung am 04.09.2025 in Berlin... ► Artikel lesen | |
| CRONOS GROUP | 2,188 | -0,73 % | CRONOS - Cannabis-Aktie explodiert ans Rallyziel! | ||
| VIATRIS | 8,688 | +0,46 % | Viatris: The Importance of a Global, Resilient Supply Chain to Access | NORTHAMPTON, MA / ACCESS Newswire / September 30, 2025 / People everywhere need access to the right treatment at the right time. However, far too many people face barriers getting the care they need.... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 11,540 | -0,86 % | EyePoint stock rating reiterated at Outperform by Mizuho amid competitor review | ||
| INCYTE | 73,60 | -0,35 % | INCYTE CORP - 8-K, Current Report | ||
| BAUSCH HEALTH | 5,740 | +0,74 % | Bausch Health Companies Inc.: Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV | The Balancing Act airing on Lifetime will showcase how innovative treatments Thermage® FLX, Clear + Brilliant®, and Fraxel FTX offer energy-based treatment options that help maintain a youthful appearance... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 66,15 | +0,05 % | Edwards Lifesciences Corporation: Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care | Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for valvular heart disease, which establish a simplified care pathway for all severe aortic stenosis (AS) patients, regardless... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 58,12 | -0,65 % | Ionis Pharmaceuticals, Inc.: TRYNGOLZA (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS) | Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that TRYNGOLZA® (olezarsen) has been approved in the European Union (EU) as an adjunct to diet in adult patients for the treatment... ► Artikel lesen | |
| CRESCO LABS | 1,256 | +7,08 % | Cresco Labs Inc. - 6-K, Report of foreign issuer | ||
| HAPPY BELLY FOOD GROUP | 0,835 | +0,60 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces Phase II Executive and Board Compensation Plan to Drive Long-Term Shareholder Value | Toronto, Ontario--(Newsfile Corp. - October 3, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen |
Das Unternehmen INVENTIVA SA ADR kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 5,250 Euro und damit +3,96 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.